These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 18848503)

  • 21. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
    Seiderer J; Göke B; Ochsenkühn T
    Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
    Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
    Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
    Bermejo F; López San Román A; Algaba A; van Domselaar M; Carneros JA; Rivero M; Piqueras B; Valer MP
    Gastroenterol Hepatol; 2008 Dec; 31(10):629-32. PubMed ID: 19174078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with biologic therapies and the risk of cancer in patients with IBD.
    Biancone L; Calabrese E; Petruzziello C; Pallone F
    Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
    Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
    J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab].
    Martín De Carpi J; Varea V
    An Pediatr (Barc); 2009 Mar; 70(3):271-7. PubMed ID: 19409244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
    Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
    Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
    Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study.
    Bernstein CN; Wajda A; Blanchard JF
    Clin Gastroenterol Hepatol; 2008 Jan; 6(1):41-5. PubMed ID: 18063423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease.
    Mamula P; Markowitz JE; Piccoli DA; Klimov A; Cohen L; Baldassano RN
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):851-6. PubMed ID: 17544875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota.
    Jess T; Loftus EV; Velayos FS; Harmsen WS; Zinsmeister AR; Smyrk TC; Schleck CD; Tremaine WJ; Melton LJ; Munkholm P; Sandborn WJ
    Gastroenterology; 2006 Apr; 130(4):1039-46. PubMed ID: 16618397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychological stress and inflammatory bowel disease: a follow-up study in parents who lost a child in Denmark.
    Li J; Nørgard B; Precht DH; Olsen J
    Am J Gastroenterol; 2004 Jun; 99(6):1129-33. PubMed ID: 15180736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
    Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS
    Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
    Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C
    Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
    Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
    Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study.
    Ott C; Obermeier F; Thieler S; Kemptner D; Bauer A; Schölmerich J; Rogler G; Timmer A
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):917-23. PubMed ID: 18794607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab for ulcerative colitis in children and adolescents.
    McGinnis JK; Murray KF
    J Clin Gastroenterol; 2008 Sep; 42(8):875-9. PubMed ID: 18645529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis.
    Gradel KO; Nielsen HL; Schønheyder HC; Ejlertsen T; Kristensen B; Nielsen H
    Gastroenterology; 2009 Aug; 137(2):495-501. PubMed ID: 19361507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.